Ligand Pharmaceuticals (LGND) Insider Trading & Ownership $119.19 +2.64 (+2.27%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ligand Pharmaceuticals (NASDAQ:LGND) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.90%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$243,475.00Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$7.56 M Get LGND Insider Trade Alerts Want to know when executives and insiders are buying or selling Ligand Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address LGND Insider Buying and Selling by Quarter Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Ligand Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/23/2024Andrew ReardonInsiderSell2,000$99.60$199,200.00 9/23/2024Matthew E KorenbergCOOSell9,772$101.22$989,121.84 9/20/2024Matthew E KorenbergCOOSell6,275$104.10$653,227.50 9/20/2024Octavio EspinozaCFOSell1,275$103.94$132,523.50 8/28/2024Andrew ReardonInsiderSell1,500$106.39$159,585.00 8/26/2024Matthew E KorenbergCOOSell11,389$105.61$1,202,792.29 New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now!8/22/2024Matthew E KorenbergCOOSell1,157$105.54$122,109.78 8/9/2024Matthew E KorenbergCOOSell18,245$98.50$1,797,132.50 8/8/2024Todd C DavisCEOBuy2,500$97.39$243,475.00 5/17/2024Octavio EspinozaCFOSell5,156$86.66$446,818.96 5/15/2024Octavio EspinozaCFOSell5,873$86.01$505,136.73 5/13/2024Matthew E KorenbergInsiderSell3,440$84.54$290,817.60 5/9/2024Andrew ReardonInsiderSell10,000$83.04$830,400.00 5/9/2024Nancy Ryan GrayDirectorSell934$83.20$77,708.80 3/5/2024Stephen L SabbaDirectorSell1,893$74.30$140,649.90 2/28/2024Octavio EspinozaCFOSell140$88.46$12,384.40 (Data available from 1/1/2013 forward) LGND Insider Trading Activity - Frequently Asked Questions Who is on Ligand Pharmaceuticals's Insider Roster? The list of insiders at Ligand Pharmaceuticals includes Andrew Reardon, John L Higgins, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Nancy Ryan Gray, Octavio Espinoza, Stephen L Sabba, and Todd C Davis. Learn more on insiders at LGND. What percentage of Ligand Pharmaceuticals stock is owned by insiders? 5.90% of Ligand Pharmaceuticals stock is owned by insiders. Learn more on LGND's insider holdings. Which Ligand Pharmaceuticals insiders have been buying company stock? The following insider purchased LGND shares in the last 24 months: Todd C Davis ($480,995.00). How much insider buying is happening at Ligand Pharmaceuticals? Insiders have purchased a total of 6,500 LGND shares in the last 24 months for a total of $480,995.00 bought. Which Ligand Pharmaceuticals insiders have been selling company stock? The following insiders have sold LGND shares in the last 24 months: Andrew Reardon ($1,210,161.00), John L Higgins ($618,700.00), John W Kozarich ($833,673.28), Matthew E Korenberg ($5,055,201.51), Nancy Ryan Gray ($77,708.80), Octavio Espinoza ($1,096,863.59), and Stephen L Sabba ($634,898.94). How much insider selling is happening at Ligand Pharmaceuticals? Insiders have sold a total of 106,609 Ligand Pharmaceuticals shares in the last 24 months for a total of $9,527,207.12 sold. Ligand Pharmaceuticals Key ExecutivesMr. Matthew E. Korenberg (Age 49)President & COO Compensation: $831.77k5 recent tradesMr. Octavio Espinoza (Age 53)Chief Financial Officer Compensation: $613.59k1 recent tradesMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Compensation: $614.87kMr. Scott M. Plesha (Age 59)Chief Executive Officer Mr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More Insider Trading Tools from MarketBeat Related Companies NRIX Insider Trading TVTX Insider Trading PRAX Insider Trading ARCT Insider Trading CMPS Insider Trading STTK Insider Trading RGEN Insider Trading MDGL Insider Trading HALO Insider Trading IONS Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:LGND) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored25X predicted for “Amazon Coin” – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
